The University of North Texas System is a public university system headquartered in Dallas, Texas. It is the administrative overseer of three otherwise autonomous Texas institutions of higher learning: the University of North Texas, a comprehensive research institution based in Denton; the University of North Texas Health Science Center in Fort Worth; and the University of North Texas at Dallas in South- and Downtown Dallas..
Many play therapists routinely use Adlerian theory as their primary mode of conducting therapy with children (Lambert et al., 2007). In an age of evidenced-informed practices, research that supports or describes a treatment's effectiveness is important (Chambless & Ollendick, 2001). Because of Adlerian play therapy's popularity and the emphasis for evidence of treatment effectiveness, researchers began investigating Adlerian play therapy. A brief description of Adlerian play therapy and a description of research is provided.
Menopause is an important life-stage transition with substantial implications for health and quality of life. Menopausal hormone therapy (HT) remains among the most effective treatments for menopausal symptoms, yet clinical uptake has varied markedly over time as evidence regarding benefits and risks has evolved. The Organization for the Study of Sex Differences and the Society for Women’s Health Research outline our support for the US Food and Drug Administration’s (FDA) removal of the “black box” warning on menopausal HT labels. This important shift in federal policy supports evidence-based menopause care and reflects an evolving, evidence-responsive regulatory practice. We further call for consistent, evidence-based FDA review of whether approved product labeling adequately incorporates sex-related differences in pharmacokinetics, pharmacodynamics, and adverse event profiles, with updates to indications, dosing, and warnings where supported by robust data.
BACKGROUND:Suicidal ideation is associated with chronic pain. The need for empathy is a common theme reported by survivors of suicide attempts. AIM:To measure the association of clinical empathy with suicidal ideation among patients with chronic low back pain (CLBP). DESIGN & SETTING:A target trial emulation was performed using adult patients selected from a national pain research registry in the US from May 2018 to December 2023. METHOD:Patients who had a designated physician who provided primary health care for their pain were followed for 12 months. Clinical empathy was assessed using the Consultation and Relational Empathy (CARE) measure. Propensity-score matching of 936 registry patients without suicidal ideation at baseline yielded 185 patients each in the greater clinical empathy (GCE) group and the lesser clinical empathy (LCE) group. Suicidal ideation and helplessness were measured with the Pain Catastrophizing Scale. RESULTS:The median age of patients was 55 years (interquartile range [IQR] 42-64 years) and 281 (75.9%) were female. Twenty-seven (14.6%) patients in the GCE group and 45 (24.3%) patients in the LCE group expressed suicidal ideation (relative risk [RR] 0.60, 95% confidence interval [CI] = 0.39 to 0.92; P = 0.02). Correspondingly, 140 (75.7%) patients in the GCE group and 164 (88.6%) patients in the LCE group expressed helplessness (RR 0.85, 95% CI = 0.78 to 0.94; P = 0.001). CONCLUSION:The decreased risk of suicidal ideation in the GCE group has potentially important implications for the delivery of primary health care for chronic pain. Research is needed to replicate these findings and to determine the effects of clinical empathy on suicide attempts and completed suicides.
Alzheimer's disease (AD) is defined by its characteristic neuropathological changes, which allow for diagnosis and assessment of severity. Recently, the Alzheimer's Association proposed a framework to stage AD biologically based on tau-PET. Furthermore, the framework hypothesizes a degree of alignment between biological AD severity and clinical symptom severity. We aimed to investigate the concordance between clinical and biological stages of AD and explore factors contributing to discordance using in vivo and post-mortem neuropathological data. Data from 768 amyloid-β-positive individuals were drawn from four observational cross-sectional in vivo cohorts (TRIAD, ADNI, HABS-HD and SCAN) in addition to a post-mortem autopsy dataset from the National Alzheimer's Coordinating Center (NACC; n = 3188). All in vivo participants had tau-PET imaging, clinical diagnosis and neurobehavioural assessments. Participants were assigned a biological AD stage based on their tau-PET scan according to the Alzheimer's Association revised criteria stages. The autopsy dataset included individuals with moderate-to-frequent neuritic plaques (CERAD scores 2-3), along with pre-mortem clinical and neurobehavioural data. Clinical-biological concordance was quantified using squared-weighted Cohen's κ. Ordinal and linear regression models assessed associations between biological stage and clinical severity (Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination), adjusting for age, sex and cohort. Post-mortem analyses evaluated the impact of comorbid neuropathologies on clinical-biological discordance using adjusted odds ratios and ordinal regression. Overall concordance between clinical and biological AD staging was moderate (Cohen's κ = 0.52, P < 0.001). Approximately 70% of individuals classified as cognitively unimpaired or with dementia exhibited biological stages consistent with their clinical diagnoses. In contrast, transitional decline and mild cognitive impairment groups were more heterogeneous. Notably, 25% of amyloid-β-positive individuals with mild cognitive impairment demonstrated no detectable tau-PET abnormality. Nonetheless, advanced tau-PET stage was reliably associated with clinical impairment. In the NACC autopsy dataset, nearly all individuals with a more severe clinical stage than their proposed biological stage exhibited comorbid neuropathologies, including frontotemporal lobar degeneration (FTLD)-TDP-43, FTLD-tau, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebrovascular disease. The number of comorbid pathologies was strongly associated with increased odds of clinical dementia (t = 8.45, P < 0.001). Although there is moderate agreement between clinical and biological stages of AD across the entire disease spectrum, strong agreement is found in clinically unimpaired and dementia stages. Comparison of clinical and biological AD stages provides a framework for understanding the large contributions of non-AD neurodegenerative diseases to dementia in amyloid-β-positive individuals. Our results have important implications for clinical trial recruitment strategies and highlight the urgent need for biomarkers for non-AD pathological processes.
Synthetic cannabinoids (SC) are created as alternatives to delta-9-tetrahydrocannabinol (∆9-THC) and can cause serious side effects like hallucinations and death. The DEA has identified eleven concerning synthetic cannabinoids: ADB-BUTINACA, ADB-HEXINACA, ADB-4en-PINACA, ADB-FUBIATA, 4F-MDMB-BICA, 4F-ABUTINACA, FUB-144, FUB-AKB-48, 5F-EMB-PICA, 5Cl-AKB-48, and MDA-19. These compounds were tested in rodent models to evaluate their effects on locomotion, discrimination, and potency relative to ∆9-THC. The eleven SC were tested for locomotor activity in Swiss-Webster mice and drug discrimination (DD) in Sprague–Dawley rats trained to discriminate ∆9 THC. In tests for locomotor depression, all the test compounds were more potent than ∆9-THC (ED50 = 3.3 mg/kg) except for FUB-144, 5Cl-AKB-48, and ADB-FUBIATA (ED50 > 6.1 mg/kg), which produced weak locomotor depressant effects. Similarly, in the DD assay, most compounds substituted fully with greater potency t than ∆9 -THC (ED50 = 0.55 mg/kg) except for FUB-144 (ED50 = 1.44 mg/kg), and 5Cl-AKB-48 (ED50 = 3.21 mg/kg). ADB-FUBIATA and MDA-19 tested in doses up to 100 mg/kg, failed to fully substitute for the discriminative stimulus of ∆9-THC. In summary, slight structural differences led to shifts in behavioral pharmacology outcomes in rodent models, which helped predict their potency relative to ∆9-THC. Therefore, future research on emerging SCs, along with structure–activity relationships at the receptor level, should include behavioral pharmacology testing of SCs to better predict their abuse potential and toxicity. Supported by NIDA contract N01DA-18–8936; N01DA-23–8936.